Trial · NCT07895017
Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
NCT07895017, Phase 2, Not yet recruiting, University of Virginia
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias. Trials, record NCT07895017. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895017
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Time-limited Treatment With Avatrombopag Pre- and Post-CAR T-cell Therapy to Prevent Post-CAR T-cell Cytopenias
- NCT number
- NCT07895017
- Status
- Not yet recruiting
- Phases
- Phase 2
- Enrollment
- 26 participants, estimated
- Lead sponsor
- University of Virginia
- Conditions
- Thrombocytopenia
- Interventions
- Avatrombopag
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with platelets ≥50K | From enrollment to Day 35 | Number of participants with platelets ≥50K for 2 consecutive laboratory checks within 1 week, and one of those measures occurring at day 28. The last platelet transfusion must be \>2 days from the first day of platelets ≥50K. |
| Secondary | Number of participants with platelets ≥30K at day 28 | From time of enrollment to day 28 | Number of participants with platelets ≥30K at day 28 |
| Secondary | Number of participants with platelets ≥30K at day 14 | From time of enrollment to day 14 | Number of participants with platelets ≥30K at day 14 |
| Secondary | Platelets ≥100K at day 28 | From enrollment to day 28 | Platelets ≥100K at day 28 |
| Secondary | Platelet transfusion independence | From day of first platelet transfusion until first day of platelets ≥10K without transfusion for 24 hours prior | Days from first platelet transfusion to first day of platelets ≥10K without transfusion for 24 hours prior |
| Secondary | Length of stay | From Day 0 to Day 60 | Number of inpatient days from Day 0 to Day 60 |
| Secondary | ≥ grade 3 AEs related to drug | From Day -10 to Day 60 | ≥ grade 3 AEs related to drug; unacceptable toxicities leading to discontinuation of drug |
| Secondary | Post infusion CRS | From Day 0 to Day 90 | CRS graded per ASTCT guidelines after infusion of CAR T cell therapy |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895017
GET https://conductscience.org/api/trials/v1/NCT07895017/registered